PRM-151

Status
Phase 3
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Intravenous (IV) Injection
Funder Type
Industry

Drug Details

PRM-151 is recombinant human pentraxin-2 (rhPTX-2), a novel antifibrotic agent with activity on monocyte differentiation, being studied for the treatment of IPF 

Study Purpose

This Phase III Study will Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of PRM-151 Compared with Placebo in Participants with Idiopathic Pulmonary Fibrosis (IPF).

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >